Predictiv On Republic—Meet The Founder

Predictiv On Republic—Meet The Founder

Predictiv Overview

What are you working on? Can you give us a brief overview of your company?

We are building Predictiv, the most advanced personalized digital twins solutions to predict and prevent diseases and adverse drug reactions by analyzing 20,000 genes for 16,000 diseases and 300 drug reactions.

What about you? What's your background? What is the unfair advantage that will make you succeed in this industry?

I am Sajung Yun, CEO & co-founder of Predictiv. My life mission is to save the most lives. I found preventing preventable diseases was the best way to do that.

DNA is blueprint of future health. Predictiv is based on DNA analytics. I am a current adjunct professor teaching a genome analysis course at Johns Hopkins University graduate school for the last four and a half years.

The Business Model

What is your business model, and who are your customers?

We are mainly B2B solution. Through telemedicine partnerships, we make personalized preventive screening and consulting plan for the next 20 years and the customers become recurring customers. We are also discussing with concierge medicine clinics.

Did you already find a product-market fit? How do you acquire and retain your customers?

Telemedicine companies are eager to make partnerships with Predictiv as they can reduce churn rate. That was how we made contracts with 200 hospitals and 3,300 physicians through telemedicine companies.

The Market

How big is your operating market? Could you provide some independent research/insights?

67% of US adults indicated they were interested in DNA testing.

TAM:

It is a $71 billon market. (report)

SOM:

It is a $14 billion market as we consider healthcare related "genetic testing" & "bioinformatics analysis" markets.

What's your competitive advantage, and how are you going to build a sustainable economic moat?

We automatized whole genome analysis process. It made us ready for scaling and reduced costs dramatically. (Reference: Predictiv $790 vs. $7,000 genetic test, https://www.waff.com/story/34679984/hudsonalpha-offering-individual-access-to-genetic-sequencing/)

The Team

Who is on your team? Is there a fun story behind it? If so, We'd love to hear more!

Sijung Yun (CSO) is Sajung's brother who is a faculty at Hopkins and FAES National Institutes of Health graduate school teaching Next Generation Sequencing analytics course.

Alex Rochegude (COO) used to be the youngest partner at entire Europe for KPMG and has two successful exits while growing his first company (Flashiz) from 0 user to 160,000 users within 25 months as CEO. His second company (Khube)he founded was the first Fintech accelerator in Europe and which it was successfully acquired by KPMG.

Mhy-Lanie Adduru (CMO) is a M.D. physician with bioinformatics training from Johns Hopkins University.

Alexander Brelsfoard (CTO) is a full-stack software developer who has lead technical team before as CTO while growing his team from 1 person to 30 people. He also worked on human genome project.

The Future

Where do you see you 5-10 years from now? What's your exit strategy?

We are predicting that everyone would need digital twins. They will use their digital twins to simulate drugs effects before taking any medications. Also, it will provide relevant genetic background information when certain signs and symptoms are present.

Genetics companies like Invitae or 23andme are good candidates to acquire. In 2020, Ancestry got acquired with $4.7B. In 2020, ArcherDX got acquired with $1.4B by Invitae. In 2017, Ambry Genetics got acquired with $1B by Konica Minolta.

As for IPO, Invitae was incorporated at 2010 and did IPO at 2015. Centogene was incorporated 2006 and they did IPO at 2019.

What do you believe is the biggest risk for the company?

Currently FDA is not regulating this software as Predictiv belongs to Software as a Medical Device category 1 and 2 level 1 and 2. The limitation is that we can market as information providing system, not as a diagnostics although we use the same technology as diagnostics. If FDA makes more strict restrictions, then we have to go through 510K or denovo. We are planning to do it later stage, not now.

Did I Invest In Predictiv?

I’m still in the process of writing a full deal report and decide whether or not I will invest in Predictiv. I review 100+ startups on 10+ platforms every month and send a detailed report every Saturday to subscribers of the Angel Notes newsletter (you can join through the form below). See you soon!

Table of Contents
Great! Next, complete checkout for full access to Angel Notes.
Welcome back! You've successfully signed in.
You've successfully subscribed to Angel Notes.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.